CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 250 enrolled
Drug / intervention
contact lens with ketotifen +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00889252
NCT00889252Phase 3Completed

A Single-Center, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Evaluating the Safety of a Novel Contact Lens Used Daily in Healthy, Normal Volunteers

Vistakon Pharmaceuticals·interventional·Posted Apr 28, 2009·Updated Mar 6, 2015

In Brief

A Phase 3 clinical trial evaluating contact lens with ketotifen and contact lens for Allergic Conjunctivitis. Completed, enrolled 250 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety of a novel contact lens in healthy normal volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 28, 2009
Enrollment StartApr 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.2 years ago

Interventions

contact lens with ketotifendevice

K-Lens (generic name not established) and Ketotifen combination drug-device product

contact lensdevice

Placebo contact lens